The detection of high levels of HER2-specific autoantibodies in a cohort of breast cancer patients positively correlated with the infiltration of B cells (CD20+) and of CXCL13+ cells, suggestive of TLS presence (Sato et al., 2021). This evidence concerns the gene ERBB2 and breast carcinoma.